Lutz Naehrlich1, Annalisa Orenti2, Fiona Dunlevy3, Irena Kasmi4, Satenik Harutyunyan5, Andreas Pfleger6, Svetlana Keegan7, Géraldine Daneau8, Guergana Petrova9, Duška Tješić-Drinković10, Panayiotis Yiallouros11, Alena Bilkova12, Hanne Vebert Olesen13, Pierre-Régis Burgel14, Tsitsino Parulava15, Filia Diamantea16, Andrea Párniczky17, Edward F McKone18, Meir Mei-Zahav19, Marco Salvatore20, Carla Colombo21, Elina Aleksejeva22, Kestutis Malakauskas23, Marc Schlesser24, Stojka Fustik25, Oxana Turcu26, Domenique Zomer-van Ommen27, Anita Senstad Wathne28, Łukasz Woźniacki29, Luísa Pereira30, Liviu Pop31, Nataliya Kashirskaya32, Milan Rodić33, Hana Kayserova34, Uro Krivecs35, Pedro Mondejar-Lopez36, Isabelle de Monestrol37, Deniz Dogru38, Halyna Makukh39, Rebecca Cosgriff40, Silke van Koningsbruggen-Rietschel41, Andreas Jung42. 1. Universities of Giessen and Marburg Lung Center, German Center of Lung Research, Justus-Liebig-University Giessen, Giessen, Germany. 2. Department of Clinical Sciences and Community Health, Laboratory of Medical Statistics, Epidemiology and Biometry G. A. Maccacaro, University of Milan, Milan, Italy. 3. European Cystic Fibrosis Society, Karup, Denmark. 4. "Mother Thereza" Hospital Center, Department of Paediatrics, Tirana, Albania. 5. Yerevan University CF Centre, Muratsan Hospital, Yerevan, Armenia. 6. Department of Pediatrics and Adolescent Medicine, Division of Pediatric Pulmonology and Allergology, Medical University of Graz, Graz, Austria. 7. Belarusian Republic Children's Center of Pulmonology and Cystic Fibrosis, Pulmonary Department, 3rd City Children's Clinical Hospital, Minsk, Belarus. 8. Sciensano, Epidemiology and public health, Health services research, Brussels, Belgium. 9. Alexandrovska University Hospital, Pediatric Clinic, Sofia, Bulgaria. 10. University Hospital Centre Zagreb, Cystic Fibrosis Centre - Paediatrics and Adults, Zagreb, Croatia. 11. Medical School, University of Cyprus, Nicosia, Cyprus. 12. Cystic Fibrosis Registry of the Czech Republic, Prague, Czech Republic. 13. Department of Pediatrics and Adolescent Medicine, Cystic Fibrosis Center, Aarhus University Hospital, Aarhus, Denmark. 14. Respiratory Medicine and National Cystic Fibrosis Reference Center, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Université de Paris, Institut Cochin, INSERM U1016, Paris, France. 15. I. Tsitsishvili Children's Clinic, CF Centre, Tblisi, Georgia. 16. Sismanoglio General Hospital of Attica, Adult Cystic Fibrosis Unit, Athens, Greece. 17. Heim Pál National Pediatric Institute, Budapest, Hungary; Institute for Translational Medicine, University of Pécs, Medical School, Pécs, Hungary. 18. St. Vincent's University Hospital & University College Dublin School of Medicine, Dublin, Ireland. 19. Pulmonary Institute, Schneider Children's Medical Center of Israel, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 20. Undiagnosed Rare Diseases Interdepartmental Unit, National Center Rare Diseases, Istituto Superiore di Sanità, Rome, Italy. 21. Cystic Fibrosis Regional Reference Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy. 22. Department of Pneumology, Children's Clinical University Hospital, Rīga Stradinš University, Riga, Latvia. 23. Adult Cystic Fibrosis center, Department of Pulmonology, Lithuanian University of Health Sciences, Kaunas, Lithuania. 24. Department of Pulmonology, Hôpital Robert Schuman, Luxembourg, Luxembourg. 25. Centre for Cystic Fibrosis, University Children's Hospital, Skopje, North Macedonia. 26. Ambulatory Cystic Fibrosis and Other Rare Diseases Center, Institute for Maternal and Child Healthcare, State University of Medicine and Pharmacy "Nicolae Testemitanu", Department of Pediatrics, Chisinau, Republic of Moldova. 27. Dutch Cystic Fibrosis Foundation (NCFS), Baarn, The Netherlands. 28. Norwegian Resource Centre for Cystic Fibrosis, Oslo University Hospital, Oslo, Norway. 29. Dziekanow Paediatric Hospital, Cystic Fibrosis Centre, Institute of Mother and Child, Warsaw, Poland. 30. Centre for Cystic Fibrosis, Hospital de Santa Maria, Lisbon, Portugal. 31. Victor Babes University of Medicine and Pharmacy Timisoara, National Cystic Fibrosis Centre Timisoara, Romania. 32. Laboratory of genetic epidemiology, "Research Centre for Medical Genetics", Moscow, Russian Federation. 33. National Centre for Cystic Fibrosis, Mother and Child Health Institute of Serbia "Dr Vukan Čupić", Belgrade, Serbia. 34. Cystic Fibrosis Centre, University Hospital of Bratislava, Bratislava, Slovakia. 35. Department of Paediatric Pulmonology, University Children's Hospital, Ljubljana University Medical Centre, Ljubljana, Slovenia. 36. Pediatric Pulmonology and Cystic Fibrosis Unit, Virgen de la Arrixaca Clinic University Hospital, Murcia, Spain. 37. Stockholm CF centre, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden. 38. Cystic Fibrosis Registry of Turkey, Ankara, Turkey. 39. Institute of Hereditary Pathology Ukrainian National Academy of Medical Sciences, Lviv, Ukraine. 40. Cystic Fibrosis Trust, London, UK. 41. CF-Center, University of Cologne, Faculty of Medicine, Cologne, Germany. 42. Paediatric Pulmonology, University Children`s Hospital Zurich, Zurich, Switzerland.
Abstract
BACKGROUND: Viral infections can cause significant morbidity in cystic fibrosis (CF). The current Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic could therefore have a serious impact on the health of people with CF (pwCF). METHODS: We used the 38-country European Cystic Fibrosis Society Patient Registry (ECFSPR) to collect case data about pwCF and SARS-CoV-2 infection. RESULTS: Up to 30 June 2020, 16 countries reported 130 SARS-CoV-2 cases in people with CF, yielding an incidence of 2.70/1000 pwCF. Incidence was higher in lung-transplanted patients (n=23) versus non-transplanted patients (n=107) (8.43 versus 2.36 cases/1000). Incidence was higher in pwCF versus the age-matched general population in the age groups <15, 15-24, and 25-49 years (p<0.001), with similar trends for pwCF with and without lung transplant. Compared to the general population, pwCF (regardless of transplantation status) had significantly higher rates of admission to hospital for all age groups with available data, and higher rates of intensive care, although not statistically significant. Most pwCF recovered (96.2%), however 5 died, of whom 3 were lung transplant recipients. The case fatality rate for pwCF (3.85%, 95% CI: 1.26-8.75) was non-significantly lower than that of the general population (7.46%; p=0.133). CONCLUSIONS: SARS-CoV-2 infection can result in severe illness and death for pwCF, even for younger patients and especially for lung transplant recipients. PwCF should continue to shield from infection and should be prioritized for vaccination.
BACKGROUND:Viral infections can cause significant morbidity in cystic fibrosis (CF). The current Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic could therefore have a serious impact on the health of people with CF (pwCF). METHODS: We used the 38-country European Cystic Fibrosis SocietyPatient Registry (ECFSPR) to collect case data about pwCF and SARS-CoV-2 infection. RESULTS: Up to 30 June 2020, 16 countries reported 130 SARS-CoV-2 cases in people with CF, yielding an incidence of 2.70/1000 pwCF. Incidence was higher in lung-transplanted patients (n=23) versus non-transplanted patients (n=107) (8.43 versus 2.36 cases/1000). Incidence was higher in pwCF versus the age-matched general population in the age groups <15, 15-24, and 25-49 years (p<0.001), with similar trends for pwCF with and without lung transplant. Compared to the general population, pwCF (regardless of transplantation status) had significantly higher rates of admission to hospital for all age groups with available data, and higher rates of intensive care, although not statistically significant. Most pwCF recovered (96.2%), however 5 died, of whom 3 were lung transplant recipients. The case fatality rate for pwCF (3.85%, 95% CI: 1.26-8.75) was non-significantly lower than that of the general population (7.46%; p=0.133). CONCLUSIONS:SARS-CoV-2 infection can result in severe illness and death for pwCF, even for younger patients and especially for lung transplant recipients. PwCF should continue to shield from infection and should be prioritized for vaccination.
Authors: Andreas Jung; Annalisa Orenti; Fiona Dunlevy; Elina Aleksejeva; Egil Bakkeheim; Vladimir Bobrovnichy; Siobhán B Carr; Carla Colombo; Harriet Corvol; Rebecca Cosgriff; Géraldine Daneau; Deniz Dogru; Pavel Drevinek; Andrea Dugac Vukic; Isabelle Fajac; Alice Fox; Stojka Fustik; Vincent Gulmans; Satenik Harutyunyan; Elpis Hatziagorou; Irena Kasmi; Hana Kayserová; Elena Kondratyeva; Uroš Krivec; Halyna Makukh; Kestutis Malakauskas; Edward F McKone; Meir Mei-Zahav; Isabelle de Monestrol; Hanne Vebert Olesen; Rita Padoan; Tsitsino Parulava; Maria Dolores Pastor-Vivero; Luísa Pereira; Guergana Petrova; Andreas Pfleger; Liviu Pop; Jacqui G van Rens; Milan Rodic; Marc Schlesser; Valérie Storms; Oxana Turcu; Lukasz Woz Niacki; Panayiotis Yiallouros; Anna Zolin; Damian G Downey; Lutz Naehrlich Journal: ERJ Open Res Date: 2021-12-27
Authors: Eusebi Chiner-Vives; Rosa Cordovilla-Pérez; David de la Rosa-Carrillo; Marta García-Clemente; José Luis Izquierdo-Alonso; Remedios Otero-Candelera; Luis Pérez-de Llano; Jacobo Sellares-Torres; José Ignacio de Granda-Orive Journal: Arch Bronconeumol Date: 2022-04-15 Impact factor: 6.333
Authors: Vito Terlizzi; Marco Antonio Motisi; Roberta Pellegrino; Rita Padoan; Elena Chiappini Journal: Front Pediatr Date: 2022-08-08 Impact factor: 3.569
Authors: Laertis Ikonomou; Mattias Magnusson; Ruben Dries; Erica L Herzog; Robert E Hynds; Zea Borok; Jin-Ah Park; Steven Skolasinski; Janette K Burgess; Leigh Turner; Sarah M Mojarad; John E Mahoney; Thomas Lynch; Mareike Lehmann; Victor J Thannickal; Jamie L Hook; Andrew E Vaughan; Evan T Hoffman; Daniel J Weiss; Amy L Ryan Journal: Am J Physiol Lung Cell Mol Physiol Date: 2022-06-28 Impact factor: 6.011